Unjha Formulations Ltd

After a sustained rally over the past nine sessions, Unjha Formulations Ltd surged to a fresh 52-week high of Rs 35.39 on 9 Sep 2026, marking a 42.19% gain since its recent low. This price milestone is underpinned by a confluence of bullish technical indicators and robust price momentum, setting the stock apart in a market environment where the broader Sensex has been under pressure.

With a decisive surge to Rs 33.4 on 8 Sep 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a 91% rally from its low of Rs 17.52 over the past year. This milestone is underscored by a strong alignment of technical indicators and sustained price momentum, even as the broader market struggles to hold ground.

Surging to a fresh 52-week high of Rs 32 on 7 Sep 2026, Unjha Formulations Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market despite a subdued Sensex environment.

Surging to a fresh 52-week high of Rs 30.5 on 4 Sep 2026, Unjha Formulations Ltd has demonstrated remarkable price momentum, outperforming its sector and the broader market over the past week and beyond.

Unjha Formulations Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a reassessment across key parameters including technical trends, valuation metrics, financial performance, and overall quality. Despite recent price gains and market-beating returns, the company’s micro-cap status and flat quarterly results have weighed on its outlook, prompting a cautious stance from analysts.

Unjha Formulations Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade amid evolving market dynamics. This change reflects a recalibration of investor sentiment, driven by adjustments in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, when compared to both historical levels and peer benchmarks within the Pharmaceuticals & Biotechnology sector.

Unjha Formulations Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and valuation metrics despite flat recent financial performance. The upgrade, effective from 28 August 2026, is driven primarily by bullish technical trends, attractive valuation relative to peers, and a stable financial outlook, positioning the micro-cap pharmaceutical company for cautious optimism among investors.

Unjha Formulations Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating. This change reflects a recalibration of price-to-earnings and price-to-book value multiples relative to historical averages and peer benchmarks, offering investors a fresh perspective on the stock’s price attractiveness amid a challenging market backdrop.

Unjha Formulations Ltd has seen its investment rating upgraded from Strong Sell to Sell, reflecting notable improvements in technical indicators and a shift in valuation metrics. Despite flat financial performance in the recent quarter, the company’s stock has demonstrated resilience with market-beating returns over multiple time horizons, prompting a reassessment of its investment appeal.

Unjha Formulations Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a fair valuation grade amid a strong market performance. This change reflects evolving investor perceptions in the Pharmaceuticals & Biotechnology sector, with key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios signalling a recalibration of price attractiveness relative to historical and peer benchmarks.

Unjha Formulations Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026, reflecting a complex interplay of technical, valuation, financial trend, and quality factors. Despite an attractive valuation and solid long-term returns, recent technical signals and flat quarterly financials have raised concerns among analysts, prompting a reassessment of the stock’s outlook.

Unjha Formulations Ltd., a Gujarat-based pharmaceutical company specialising in Isabgol (Psyllium) formulations, reported a marginal improvement in its Q1 FY27 results, posting a net profit of ₹0.16 crores, a modest recovery from the loss-making Q4 FY26. However, the company's performance remains marred by persistent volatility and declining year-on-year metrics, raising questions about its operational stability and growth trajectory.

Unjha Formulations Ltd has witnessed a notable improvement in its valuation parameters, shifting from a very attractive to an attractive rating, signalling a positive change in price attractiveness amid a challenging pharmaceuticals sector. This micro-cap stock’s recent performance and valuation metrics merit close attention from investors seeking value in the Pharmaceuticals & Biotechnology space.

With a decisive surge to Rs 29.5 on 30 Jul 2026, Unjha Formulations Ltd has reached a fresh 52-week high, marking a significant milestone in its price momentum. This rally comes after a sustained four-day gain, delivering a 23.9% return in that period and outpacing its sector by over 7% today alone.